NEW YORK, July 2, 2014 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of STAAR Surgical Company ("STAAR" or the "Company") (NasdaqGM: STAA). The investigation focuses on whether the Company and its executives violated federal securities laws.
On July 1, 2014, the U.S. Food and Drug Administration (FDA) released a copy of a warning letter that it issued STAAR on May 21, 2014 indicating that the Company's Monrovia, California facility lacks adequate procedures for documenting design of implantable lenses for the eye. The FDA also cited failures in handling complaints, sterility testing, and keeping required records. The FDA cited findings from inspections in February-March 2014.
On this news, shares of shares of STAAR fell 1.89 or 11.25% during intraday trading to trade at $14.91.
If you are aware of any facts relating to this investigation, or purchased shares of STAAR Surgical Company, you can assist this investigation by contacting either Edward N. Gewirtz or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Edward N. Gewirtz or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC